ASH 2022 | The impact of cytogenetics and molecular genetics on outcomes in AML

Alexander Perl • 10 Dec 2022

ASH 2022

General

Alexander Perl, MD, University of Pennsylvania, Philadelphia, PA, comments on the decreasing use of cytogenetics as a method for predicting outcomes in acute myeloid leukemia (AML), contrasting it with the growing use of molecular genetics identified by next-generation sequencing (NGS). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Astellas, Daiichi Sankyo, AbbVie, Forma, Sumitomo Dainippon, BeatAML LLC: Consultancy; Astellas, Abbvie, Daiichi Sankyo, FujiFilm, Syndax: Research Funding; Astellas, Daiichi Sankyo, Abbvie, Genentech, BerGenBio, Immunogen, BMS/Celgene, Actinium: Membership on an entity’s Board of Directors or advisory committees.